1
|
Kariki O, Mililis P, Saplaouras A, Dragasis S, Patsiotis IG, Chatziantoniou A, Alexiou D, Cheilas V, Letsas KP, Efremidis M. Cryoablation versus hybrid radiofrequency with high- and very-high-power short-duration catheter ablation for the treatment of paroxysmal atrial fibrillation. Hellenic J Cardiol 2024:S1109-9666(24)00075-7. [PMID: 38554832 DOI: 10.1016/j.hjc.2024.03.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Revised: 03/20/2024] [Accepted: 03/26/2024] [Indexed: 04/02/2024] Open
Abstract
BACKGROUND High-power short-duration (HPSD) and very-high-power short-duration (vHPSD-90 W/4 s) radiofrequency (RF) technology has reduced the procedure time of pulmonary vein isolation (PVI) using RF without compromising the efficacy of the technique. The current study compares the novel technology of HPSD/vHPSD with cryoablation (CRYO) in terms of efficacy, safety, and procedure time in a cohort of symptomatic patients with paroxysmal atrial fibrillation (pAF). METHODS This is a prospective, non-randomized trial. Patients with pAF received either CRYO or HPSD/vHPSD RF PVI. The primary endpoint of the study was arrhythmia recurrence in a 12 month follow-up period. Secondary endpoints included procedure time, fluoroscopy time, and safety. RESULTS 104 patients were included (45 in HPSD/vHPSD and 59 in CRYO), with comparable characteristics between groups. The follow-up was 12.4 ± 0.5 months. There was no significant difference regarding arrhythmia recurrences during the early post-procedural period of the first 3 months (8.9% recurrences in HPSD/vHPSD versus 5.1% in CRYO-p 0.463) and in the mid-term follow-up of 12 months (17.8% recurrences in HPSD/vHPSD versus 10.2% in CRYO-p 0.385). Safety was excellent for both procedures. CRYO was a procedure of significantly shorter duration (64.64 ± 8.94 min versus 75.29 ± 18.30 min, p = 0.0001) at the expense of longer fluoroscopy time (HPSD/vHPSD 5.34 ± 1.83 versus 7.89 ± 3.70 min CRYO, p 0.001). CONCLUSIONS HPSD/vHPSD and CRYO in pAF were comparable regarding the arrhythmia recurrence rates in a 12-month follow-up with excellent safety. The hybrid approach of HPSD/vHPSD has accelerated RF-PVI compared to conventional RF, but CRYO remains a procedure of significantly shorter duration at the expense of longer fluoroscopy time.
Collapse
Affiliation(s)
- Ourania Kariki
- Arrhythmia Unit, Onassis Cardiac Surgery Center, Athens 17674, Greece
| | | | | | | | - Ilias G Patsiotis
- Arrhythmia Unit, Onassis Cardiac Surgery Center, Athens 17674, Greece
| | | | - Dimitrios Alexiou
- Arrhythmia Unit, Onassis Cardiac Surgery Center, Athens 17674, Greece
| | - Vasileios Cheilas
- Arrhythmia Unit, Onassis Cardiac Surgery Center, Athens 17674, Greece
| | | | - Michael Efremidis
- Arrhythmia Unit, Onassis Cardiac Surgery Center, Athens 17674, Greece
| |
Collapse
|
2
|
Junarta J, Rodriguez S, Ullah W, Siddiqui MU, Riley JM, Patel A, O'Neill P, Dikdan SJ, Fradin JJ, Rosen JL, Frisch DR. Comparison of very high-power short-duration, high-power short-duration, and low-power long-duration radiofrequency ablation for atrial fibrillation: A systematic review and network meta-analysis. Pacing Clin Electrophysiol 2023; 46:1609-1634. [PMID: 37971718 DOI: 10.1111/pace.14879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Accepted: 11/05/2023] [Indexed: 11/19/2023]
Abstract
BACKGROUND The optimal power and duration settings for radiofrequency (RF) atrial fibrillation (AF) ablation to improve efficacy and safety is unclear. We compared low-power long-duration (LPLD), high-power short-duration (HPSD), and very HPSD (vHPSD) RF settings for AF ablation. METHODS This network meta-analysis (NMA) was structured according to the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. Medline, Scopus and Cochrane Central Register of Controlled Trials were systematically searched to identify relevant studies. Observational and randomized studies were included. Eligible studies compared outcomes in AF patients who underwent first-time RF ablation with the following settings: vHPSD (70-90 W, 3-10 s), HPSD (45-60 W, 5-10 s), or LPLD (20-40 W, 20-60 s). RESULTS Thirty-six studies comprising 10,375 patients were included (33% female). Frequentist NMA showed LPLD tended toward a lower odds of freedom from arrhythmia (FFA) versus HPSD (OR 0.93, 95% CI 0.86-1.00). There was no difference in FFA between vHPSD versus HPSD. Splitwise interval estimates showed a lower odds of FFA in LPLD versus vHPSD on direct (OR 0.78, 95% CI 0.65-0.93) and network estimates (OR 0.85, 95% CI 0.73-0.98). Frequentist NMA showed less total procedural (TP) time with HPSD versus LPLD (generic variance 1.06, 95% CI 0.83 to 1.29) and no difference between HPSD versus vHPSD. CONCLUSION This NMA shows improved procedural times in HPSD and vHPSD versus LPLD. Although HPSD tended toward improved odds of FFA compared to LPLD, the overall result was not statistically significant. The odds of FFA in LPLD was lower versus vHPSD on direct and network estimates on splitwise interval analysis. Large prospective head-to-head randomized trials are needed to validate HPSD and vHPSD settings.
Collapse
Affiliation(s)
- Joey Junarta
- Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, USA
| | - Sebastian Rodriguez
- Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, USA
| | - Waqas Ullah
- Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, USA
| | - Muhammad U Siddiqui
- Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, USA
| | - Joshua M Riley
- Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, USA
| | - Anjani Patel
- Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, USA
| | - Parker O'Neill
- Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, USA
| | - Sean J Dikdan
- Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, USA
| | - James J Fradin
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA
| | - Jake L Rosen
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA
| | - Daniel R Frisch
- Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, USA
| |
Collapse
|
3
|
Nair D, Martinek M, Colley BJ, Sundaram S, Hariharan R, Morales G, Sommer P, Healy S, Siddiqui U, Gibson D, Chapman K, Sarver A, Lo M. Safety and effectiveness of the first contact force ablation catheter with a flexible tip. Heart Rhythm O2 2023; 4:784-793. [PMID: 38204461 PMCID: PMC10774658 DOI: 10.1016/j.hroo.2023.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2024] Open
Abstract
Background Catheter ablation is an established therapy for paroxysmal atrial fibrillation (PAF). The TactiFlex Ablation Catheter, Sensor Enabled (TactiFlex SE) is a next-generation radiofrequency ablation catheter incorporating fiber optics-based contact force-sensing technology with a flexible, laser-cut tip. Objective The study sought to evaluate the safety and effectiveness of the TactiFlex SE ablation catheter for treatment of drug-refractory PAF. Methods The TactiFlex AF investigational device exemption was a prospective, nonrandomized, multicenter clinical study. Enrollment began on June 26, 2020 and completed June 18, 2021. Subjects with PAF underwent de novo pulmonary vein isolation and, if indicated, ablation for typical atrial flutter. Subjects were followed for 12 months. Results Of the 355 subjects enrolled at 37 sites worldwide, 334 underwent ablation with the TactiFlex SE catheter. The Kaplan-Meier estimate of 12-month freedom from AF/atrial flutter (AFL)/atrial tachycardia recurrence was 72.9% (95% confidence interval [CI] 95% CI 67.2%-77.8%) and clinical success was 83.6% (95% CI 95% CI 78.1%-87.2%). As-treated analyses compared subjects treated at high power (left atrium time-averaged power setting 40-50 W; n = 222) vs low power (<40 W; n = 97). The Kaplan-Meier estimate of 12-month freedom from AF/AFL/atrial tachycardia recurrence was 76.4% (95% CI 69.3%-82.0%) and clinical success was 83.9% (95% CI 77.5%-88.6%) in the high-power group compared with 66.8% (95% CI 56.1%-75.5%) and 80.7% (95% CI 70.8%- 87.5%), respectively, in the low-power group. The primary safety event rate in all treated subjects was 4.3%; 4.1% in the HP group and 5.2% in the LP group (P = .7671). Conclusion TactiFlex SE is safe and effective for treatment of drug-refractory PAF and concomitant AFL and enables more efficient procedures than previous generation catheters.
Collapse
Affiliation(s)
- Devi Nair
- St. Bernard’s Medical Center, Jonesboro, Arkansas
| | - Martin Martinek
- Cardiology, Angiology, and Intensive Care Medicine, Ordensklinikum Linz Elisabethinen, Linz, Austria
| | | | - Sri Sundaram
- South Denver Cardiology Associates PC, Denver, Colorado
| | - Ramesh Hariharan
- University of Texas Health Science Center at Houston, Houston, Texas
| | | | - Philipp Sommer
- Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany
| | | | | | | | | | | | - Monica Lo
- Arkanasas Heart Hospital, Little Rock, Arkansas
| |
Collapse
|
4
|
Boga M, Suhai FI, Orbán G, Salló Z, Nagy KV, Szegedi L, Jokkel Z, Csőre J, Osztheimer I, Perge P, Gupta D, Merkely B, Gellér L, Szegedi N. Incidence and predictors of stroke and silent cerebral embolism following very high-power short-duration atrial fibrillation ablation. Europace 2023; 25:euad327. [PMID: 37931067 PMCID: PMC10653180 DOI: 10.1093/europace/euad327] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 08/22/2023] [Accepted: 10/02/2023] [Indexed: 11/08/2023] Open
Abstract
AIMS Cerebral thrombo-embolism is a dreaded complication of pulmonary vein isolation (PVI) for atrial fibrillation; its surrogate, silent cerebral embolism (SCE) can be detected by diffusion-weighted brain magnetic resonance imaging (bMRI). Initial investigations have raised a concern that very high-power, short-duration (vHPSD; 90 W/4 s) temperature-controlled PVI with the QDOT Micro catheter may be associated with a higher incidence of SCE compared with low-power long-duration ablation. We aimed to assess the incidence of procedural complications of vHPSD PVI with an emphasis on cerebral safety. METHODS AND RESULTS We enrolled 328 consecutive patients undergoing their PVI procedure using vHPSD. A subgroup of 61 consecutive patients underwent diffusion-weighted bMRI within 24 h of the procedure, and incidence and predictors of SCE were studied. The mean procedure time and left atrial dwell time for the overall cohort were 69.6 ± 24.1 and 46.5 ± 21.5 min, respectively. First-pass isolation was achieved in 82%. No stroke or transient ischaemic attack occurred. Silent cerebral embolism was identified in 5 of 61 patients (8.2%). Silent cerebral embolism following procedures was significantly associated with lower baseline generator impedance (105.8 vs. 112.6 Ω, P < 0.0001) and with intermittent loss of catheter-tissue contact during ablation (14.1% vs. 6.1%, P < 0.0001). CONCLUSION Very high-power, short-duration PVI is a safe technique with an excellent acute success rate. Silent cerebral embolism incidence in our cohort was below the previously reported range, with no clinically overt cerebral complications. Lower baseline generator impedance and loss of contact during ablation may contribute to a higher risk of SCEs.
Collapse
Affiliation(s)
- Márton Boga
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Ferenc Imre Suhai
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Gábor Orbán
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Zoltán Salló
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Klaudia Vivien Nagy
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Levente Szegedi
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Zsófia Jokkel
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Judit Csőre
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - István Osztheimer
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Péter Perge
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Dhiraj Gupta
- Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, UK
| | - Béla Merkely
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - László Gellér
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| | - Nándor Szegedi
- Heart and Vascular Center, Semmelweis University, Városmajor u. 68., Budapest 1122, Hungary
| |
Collapse
|